LOGIN
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis
August 2013
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
N Engl J Med. 2007 Nov 15;357(20):2028-39Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
428 patients with glucocorticoid-induced osteoporosis were randomised to receive one of two treatments. The first group received a treatment of 20 μg teriparatide daily while the second group received a 10 mg alendronate treatment. The primary outcome was change in bone mineral density at the lumbar spine from baseline to the 18-month follow-up. Results indicated that bone mineral density increas...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.